Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2008

View Archived Issues

Recent patent literature reports novel anticancer compounds

Yi-Gan San studied in dementia, tardive dyskinesia and borderline personality disorder

VaxGen and Raven terminate merger agreement

Cardiac-specific MAP kinase protects against cardiac ischemia in vitro and in vivo

Evotec and Ono sign agreement to identify compounds against a protease target

Encouraging results reported in first clinical trial of efficacy for GFT-505

Positive phase III data reported for new GnRH blocker degarelix

Avanir to raise gross proceeds of USD 40 million in a registered direct offering

MethylGene enters agreement with Otsuka for small-molecule kinase inhibitors

MPA requests additional information prior to initiation of Tripeps' ChronSeal phase II study

Thallion defers start date of phase II/III clinical trial of Shigamabs by six months

Evotec reports preliminary findings from study of EVT-101 in healthy volunteers

Seattle Genetics initiates second phase I clinical trial of SGN-35 in Hodgkin's lymphoma

New therapeutic agents for diabetic nephropathy described in recent Kowa patent

Recent Amgen and Kyowa Hakko patents disclose novel analgesic agents

IMPACT1 study demonstrates efficacy of Berinert P in hereditary angioedema

DJ-1 provides neuroprotection against oxidative stress

Effects on survival seen with EGF vaccine in non-small cell lung cancer patients

Lilly commences phase III LY-450139 trial for Alzheimer's disease

NeuroSearch initiates phase I NSD-788 study for anxiety and depression

Synosia Therapeutics commences phase II rufinamide trial for general anxiety disorder

Protectan CBLB-502 shows mitigation of hematopoietic damage post-radiation

UCB reports phase II results for CDP-791 in non-small cell lung cancer

Phase I/II trial in CF patients begins for Humaneered antibody against P. aeruginosa infections

NeoPharm enrolls first patients in phase II cancer trial of liposomal paclitaxel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 24, 2026.
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 24, 2026